Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing

TL;DR

This paper reviews how gene editing can improve CAR-T cell therapy for cancer, addressing challenges like toxicity and limited effectiveness.

Contribution

The paper provides a comprehensive review of recent advancements in gene editing for CAR-T cell therapy and outlines future directions.

Findings

Gene editing technologies like CRISPR/Cas can enhance CAR-T cell efficacy and safety.

Challenges remain in applying CAR-T therapy to solid tumors and managing toxicities.

Emerging tools like base and prime editing offer new possibilities for optimizing CAR-T cells.

Abstract

Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in cancer immunotherapy, demonstrating impressive clinical outcomes, particularly for hematologic malignancies. However, its broader therapeutic application, especially against solid tumors, remains limited. Key challenges include T cell exhaustion, limited persistence, cytokine-mediated toxicities, and logistical hurdles associated with manufacturing autologous products. Emerging gene editing technologies, such as CRISPR/Cas systems, base editing, and prime editing, offer novel approaches to optimize CAR-T cells, aiming to enhance efficacy while managing toxicity and improving accessibility. This review comprehensively examines the current landscape of these gene editing tools in CAR-T cell therapy, highlighting the latest advancements, persisting challenges, and future directions. Leveraging gene editing holds the potential to transform CAR-T therapy into a more potent, safer, and broadly applicable modality for cancer and beyond.

Figures